Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute, discusses the CREATE-X adjuvant study of capecitabine in high-risk patients with residual disease (Abstract S6-01).
Jame Abraham, MD, of the Cleveland Clinic, discusses findings on the use of avelumab, an anti–PD-L1 antibody, in patients with locally advanced or metastatic breast cancer, as well as the preliminary efficacy and safety findings of pembrolizumab in patients with PD-L1–positive, estrogen receptor–positive/HER2-negative disease (Abstracts S1-04, S5-07).
Mitchell Dowsett, PhD, of the Royal Marsden Hospital discusses the EndoPredict test, which has improved performance compared with the widely used Oncotype Dx test (Abstract S3-01).
Michael Gnant, MD, of the Medical University of Vienna, discusses a study in which denosumab was added to adjuvant aromatase inhibitor therapy to improve disease-free survival in postmenopausal patients with early-stage, hormone receptor–positive breast cancer (Abstract S2-02).
Jack Cuzick, PhD, FMedSci, of Queen Mary, University of London, discusses his phase III study on postmenopausal women with DCIS who had similar outcomes whether they took tamoxifen or anastrozole for 5 years after surgery. (Abstract S6-03)
Sarat Chandarlapaty, MD, PhD, of the Memorial Sloan Kettering Cancer Center, discusses results from this study that showed patients with ER-positive metastatic breast cancer who had a D538G and/or a Y537S mutation in the ESR1 gene had significantly worse median overall survival (Abstract S2-07).
